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Summary 
CD44 is implicated in the regulation of tumor growth and metastasis but the mechanism by 
which expression of different CD44 isoforms determines the rate of primary and secondary tumor 
growth remains unclear. In the present study we use a human melanoma transfected with wild- 
type and mutant forms of CD44 to determine which functional property of the CD44 molecule 
is critical in influencing tumor behavior. We show that expression of a wild-type CD44 isoform 
that binds hyaluronic acid augments the rapidity of tumor formation by melanoma cells in vivo, 
whereas expression of a CD44 mutant, which does not mediate cell attachment to hyaluronate, 
fails to do so. The importance of CD44-hyaluronate interaction in tumor development is underscored 
by the differential inhibitory effect of soluble wild-type and mutant CD44-Ig fusion proteins 
on melanoma growth in vivo. Whereas local administration of a mutant, nonhyaluronate binding, 
CD44-Ig fusion protein has no effect on subcutaneous melanoma growth in mice, infusion of 
wild-type CD44-Ig is shown to block tumor development. Taken together, these observations 
suggest that the tumor growth promoting property of CD44 is largely dependent on its ability 
to mediate cell attachment to hyaluronate. 
C 
D44 is a broadly distributed cell surface glycoprotein 
implicated in multiple physiologic cellular functions 
including cell-cell adhesion (1-3), lymphocyte activation (3-6), 
and cell-substrate interaction (7-11). Characterization  of the 
genomic clone of CD44 has demonstrated the existence of 
10 exons encoding a portion of the extracellular domain that 
are differentially spliced (12), giving rise to a number of iso- 
forms with different molecular masses (9,  13-17). In addi- 
tion to variable exon usage, cell type-specific glycosylation 
may contribute to structural and functional CD44 isoform 
diversity (14, 18). 
Expression of the different isoforms is not uniform. The 
most widely expressed isoform is the 80-90-kD glycopro- 
tein that represents the "standard" CD44 molecule, as it does 
not contain differentially spliced exons (13, 19). It is com- 
monly referred to as CD44H and has been shown to be a 
major cell surface  receptor for hyaluronate (8, 10, 20). CD44H 
is the principal isoform found in hematopoietic cells, fibro- 
blasts, melanomas, and some epithelial cells (9, 13, 17, 21). 
Larger isoforms that contain different combinations of differen- 
tially spliced exons have a more restricted pattern of expres- 
sion and appear to be preferentially associated with epithelial 
cell subpopulations (9, 14, 15, 17, 22). Although all isoforms 
contain  the  hyaluronate  (HA)t-binding  domain,  their 
affinity for surface-bound HA is variable (9, 23), and at least 
some of the larger isoforms appear unable to mediate attach- 
ment of cells to HA-coated surfaces (9,  11,  23). 
CD44 expression has been associated with tumor growth 
and metastasis (16, 23) but the molecular basis for this as- 
sociation has remained unclear. In the rat, expression of a 
160-kD variant form of CD44, containing variable exon 6 
which corresponds  to exon 10 of the genomic clone (12), 
has been proposed  to induce metastatic behavior in a pan- 
creatic carcinoma cell line (16). In experiments designed to 
directly test  the effect of CD44 expression on lymphoma 
growth and dissemination,  it was observed that expression 
of CD44H significantly enhanced local tumor formation in 
nude mice, whereas expression of CD44E, a 150-kD isoform 
associated with some carcinomas (9) and containing variable 
exons 8-10 (12-14 of the genomic clone) (12), failed to pro- 
mote tumor growth (23). The difference in the rapidity of 
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CD44E-expressing lymphoma cells correlates with the differ- 
ence in their capacity to adhere to surface-bound HA (9, 11, 
23). It was proposed that host tissue HA might enhance tumor 
development by providing a molecular bridge which facili- 
tates HA-receptor bearing tumor cell attachment to extracel- 
lular matrix (ECM) components.  The ECM could serve as 
a scaffold for tumor growth as well as a reservoir of growth 
factors potentially beneficial to the malignant cells (24).  In 
the present work we provide direct evidence that the capacity 
of CD44  to mediate tumor cell attachment  to hyaluronate 
determines the rate of formation of the resulting tumor mass. 
We also show that soluble CD44 can be effectively used to 
contain  local tumor  growth  in vivo. 
Materials and Methods 
Cell Lines.  Development of stable CD44 transfectants in the 
human melanoma cell line MC has been described previously (11). 
MC44H, MC44E, MC44TL, and MC-T express wild-type CD44H, 
wild-type CD44E, a cytoplasmic tail deletion mutant of CD44H, 
and pSV2neo, the selection plasmid containing the neomycin resis- 
tance gene, respectively. Additional transfectants used in this study 
include  MCcc2,6ST,  expressing  the  B-galactoside  oe-2,6-sialyl- 
transferase; MC44H41R-A, expressing the mutant CD44H which 
does not bind HA (25); and MC44H/E expressing both CD44H 
and CD44E.  These transfectants were generated by introducing 
each respective cDNA clone in a ~rH3M vector (26) modified to 
include a hygromycin resistance gene. Transfections were performed 
by electroporation (Gene Pulser; Bio-Rad Laboratories, Richmond, 
CA) using the same conditions as those for the previous transfec- 
tants (250 V, 960/~F). Clones were selected for hygromycin resis- 
tance in DMEM (Irvine Scientific, Santa Ana, CA) supplemented 
with 2 mM glutamine (GIBCO BRL, Gaithersburg, MD), 10% 
FCS (Irvine Scientific),  gentamycin, and 500/zg/ml Hygromycin 
B (Boehringer Mannheim Corp., Indianapolis,  IN). To generate 
MC44H/E double transfectants, the CD44H construct in the vector 
containing the hygromycin resistance  gene was  introduced into 
MC44E transfectants  containing the neomycin resistance gene (11). 
Clones were selected  for resistance  to hygromycin B  and G418 
(GIBCO BILL). All transfectants were periodically tested for ex- 
pression  of CD44 isoforms by indirect immunofluorescence. 
The murine B16F10 melanoma was obtained from the Amer- 
ican Type Culture Collection (Rockville, MD)  and cultured in 
DMEM  supplemented with  10%  FCS and gentamycin. 
mAbs and Polyclonal Antisera.  The anti-human  CD44  mAb 
F10-44-2, which recognizes all CD44 isoforms, was acquired from 
R & D Systems Inc. (Minneapolis,  MN). Antimurine CD44 IM7 
hybridoma was obtained from the American Type Culture Collec- 
tion. The murine mAb M-kid 2, which recognizes a conforma- 
tional epitope of the c~3B1 (very late activation antigen [VLA] 3) 
integrin has been previously described (27). mAbs to VLA1 and 
VLA4  integrins  were  kindly provided by Dr.  Martin  Hemler 
(Dana Farber Cancer Institute, Boston, MA); mAbs to VLA2 and 
VLA5 were a gift from Dr. Randy Byers (Massachusetts  General 
Hospital).  The rat mAb  to VLA6 was  purchased from Janssen 
Biochimica (Accurate Chemical & Scientific Corp., Westbury, NY). 
Immunofluorescence.  Cells were detached from plates with EDTA, 
washed, resuspended in PBS, and incubated with mAbs or poly- 
clonal antisera (30-50/zg/ml) for 45 min at 4~  Cells were washed 
in PBS, incubated with fluorescein-labeled  F(ab)2 fractions of goat 
anti-rat  or  goat  anti-mouse  affinity purified antibody (Cappel 
Laboratories, Malvern, PA) for 30 rain at 4~  washed, resuspended 
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in PBS, and analyzed on a FACS  |  (Becton Dickinson & Co., Moun- 
tain View,  CA). 
For tissue staining,  5/zm frozen tissue sections were mounted 
onto slides, air-dried,  and incubated with 10/~g/ml of each recep- 
torglobulin or human IgG for 45 rain at room temperature. The 
slides were washed in PBS, incubated with fluorescein-labeled goat 
anti-human affinity-purified antibody, washed, and examined under 
an epifluorescence  microscope (Nikon Inc., Melville,  NY). 
Adhesion Assays.  96-well tissue culture plates were coated with 
5 mg/ml hyaluronate, chondroitin sulfate,  fibronectin, collagen 
type I or collagen type VI, or heat denatured BSA overnight at 
4~  and nonspecific sites were blocked with 1 mg/ml BSA. The 
wells were washed with PBS and seeded with S*Cr-radiolabeled 
B16F10 melanoma or MC transfectant  cells (10  s cells/well) in PBS. 
Adhesion was allowed  to proceed at 4~  for 30 min. The wells 
were then washed three times with PBS, the adherent cells were 
lysed with 1% SDS, and the lysate radiolabel  was determined in 
a B-counter. In addition, 5 # thick frozen tissue sections of mouse 
and rat skin, muscle,  and kidney were prepared, mounted onto 
slides, air dried, and overlayed with MC transfectants (10  s cells/ 
slide)  resuspended in  PBS. Tissue  section adhesion  assays were 
performed at  4~  for 30  rain  with  gentle rotational shaking. 
Slides were then washed in PBS, stained with toluidine blue (Sigma 
Chemical Co., St. Louis, MO) for 1 rain, washed,  and examined 
under an epifluorescence  microscope.  Hyaluronidase treatment of 
tissues  was performed by incubating frozen tissue  sections  with 
1/~g/ml streptomycete hyaluronidase  (Calbiochem-Novabiochem, 
La Jolla, CA) in phosphate-buffered saline for 1 h at 37~  Ker- 
atanase (0.5 U/ml) and heparitinase  (0.01 U/ml) control digestions 
were performed under the same conditions. 
Preparation of CD44 receptorglobulins and full-length  CD44H mu- 
tant. CD44HRg (8), CD44HMutR.g (24),  and CD44ERg were 
prepared as previously described. Briefly, synthetic oligonucleotide- 
primed amplification of cDNA sequences encoding the extracel- 
lular sequences of CD44H and CD44H41R-A was performed by 
PCR.  Oligonucleotide  primers  were  designed  to  contain  en- 
donuclease  restriction sites  to facilitate  subsequent  insertion of 
amplified sequences in Ig expression vectors. Amplified CD44 se- 
quences were subjected to appropriate restriction endonuclease diges- 
tion and ligated to Ig vectors previously subjected to corresponding 
endonuclease cleavage. CD44-Ig constructs were introduced into 
COS cells by the DEAE-Dextran method (8), and 5-8 d post trans- 
fection supernatants were harvested and receptorglobulins purified 
on protein A sepharose beads (Repligen, Cambridge, MA). Recep- 
torglobulins were eluted with 0.1 M citric acid, pH 3.0, dialyzed 
overnight and purified protein concentration determined in ELISA 
assays (Amersham Corp., Arlington Heights, IL). To synthesize 
a full-length CD44H41R-A cDNA (including the transmembrane 
and intracytoplasmic domain-encoding segments),  the Ig construct 
containing the mutant was digested with HindIII and AlwnI. The 
resulting fragment was mixed with an AlwnI/NotI-digested frag- 
ment derived from a vector containing full-length CD44H, and 
ligated  together in  a  three-way ligation  with  a HindIII/NotI- 
digested CDM8 vector modified to contain a hygromycin resistance 
gene. 
Determination of Cellular Growth Rate In Vitro.  Each transfec- 
tant was cultured in 96-well flat-bottomed microtiter plates (Falcon 
Labware, Oxnard, CA) at a concentration of 5  x  104 cells/well 
in DMEM/10% FBS. After 24 h of culture, cells were pulsed with 
1/~Ci of [3H]thymidine, cultured for an additional 24 h, harvested 
with an automatic pH.D harvester (Cambridge Bioscience, Cam- 
bridge,  MA)  and  [3H]thymidine incorporation determined in  a 
B-counter. All cultures were done in triplicate. 
Evaluation of Tumor Growth In Viva  Pathogen-free 4-5-wk-old 
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of in vivo tumor growth. MC melanoma transfectants were detached 
from tissue culture plates with EDTA, washed in sterile PBS and 
injected  subcutaneously  into  SCID mice  at  a concentration  of 
6 x 1@ ceUs/0.2 ml. Animals were examined three times a week 
for signs ofcalibrable tumor growth and were killed after 36-40 d 
and an autopsy performed. Tumor weight before autopsy was cal- 
culated  by the  formula  (d  2  x  D)/2,  where  d  represents  the 
smallest and D the largest diameter of the tumor.  To determine 
the role of CD44 in the promotion of B16F10 melanoma growth, 
nude mice were used (described below). 
Blocking of Tumor Growth with Soluble CD44.  Each animal was 
anesthesized  with  2,2-dichloro-l,l-difluoroethyl-methyl  ether 
(methoxyflurane) (Pitman-Moure,  Inc., Mundelein, IL) in a semi- 
dosed system and a single ALZET osmotic pump 1007D (Alza 
Corp., Palo Alto, CA), filled with 600/~g/0.1 ml of CD44HRg, 
CD44H41ARg, or human IgG, was implanted subcutaneously in 
the retroscapular region.  Six mice/group  were used. ALZET os- 
motic pumps 1007D are designed to deliver a fixed volume of 0.5 
/~l/h for a period of 7 d. The amount of receptorglobulin  or IgG 
delivered is expressed by the formula k  =  Q  x  Cd, where k is 
the mass delivery rate, Cd the concentration  of the molecule used 
to fill the pump and Q the pumping rate (0.5 #g/h for the 1007D 
model). In this system, 3/~g/h of each receptorglobulin  or IgG 
were delivered for 7 d. On the day after the implantation  of the 
pump, B16F10 melanoma cells were detached with EDTA, washed 
in PBS, resuspended in CD44HILg, CD44Mut Rg, or human IgG 
at 125  x  103 ceUs/0.2 ml, and injected into the pocket containing 
the pump. Mice were killed at 8 and 14 d after the injection and 
tumor growth was assessed. 
Radiolabeling and Iramunoprecipitation.  MC melanoma transfec- 
tants were washed and cultured in methionine-free medium (GIBCO 
BILL) supplemented with 10% dialyzed FCS for 2 h. Cells were 
then  pulsed  with  250  /zCi/ml  of [35S]methionine (Amersham 
Corp.) for 12 h, washed in PBS, detached,  and lysed in a buffer 
containing  1%  Triton  X-100, 10  /xg/ml  leupeptin,  100  U/ml 
aprotinin (all from Sigma Chemical Co.) and 10/~M PMSF (Bethesda 
Research Laboratories Inc., Bethesda, MD). After 1 h of lysis at 
4~  nuclei  were removed by centrifugation  and  lysates were 
precleared with protein A-Sepharose CL4B (Pharmada LKB, Upp- 
sala, Sweden) coated with affinity purified rabbit anti-mouse IgG 
(Sigma Chemical Co.).  After preclearing, lysates were incubated 
with protein A-Sepharose CL4B coated with anti-CD44 mAb F10- 
44-2 for 1 h at 4~  the protein A-Sepharose beads washed, and 
the precipitates eluted by boiling.  Immunoprecipitates  were ana- 
lyzed by SDS/7.5% PAGE. The gels were fixed, dried, and sub- 
jected to autoradiography. 
To determine CD44 shedding, equal numbers of MC-T, MC44H, 
MC44E,  and  MC44H/E  transfectants  were  radiolabeled with 
[3SS]methionine as above. 72 h after radiolabeling, culture  super- 
natants were harvested, precleared, and incubated with anti-CD44 
mAb F10-44-2 and protein  A-Sepharose beads (Pharmacia LKB) 
at 4~  overnight.  The beads were washed and precipitates eluted 
and analyzed by SDS-PAGE and autoradiography  as above. 
Results 
A  Soluble Form ofa CD44H Mutant Does Not Bind Ligands 
In Vivo.  Development of soluble CD44-Ig fusion proteins 
(termed  CD44Rg,  for receptorglobulins)  has been instru- 
mental in determining that CD44 is a receptor for hyaluronate 
(8). Recently, CD44HtLg has been subjected to site-specific 
mutagenesis (25) and a single point mutation which modifies 
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residue 41 from an arginine to an alanine has been observed 
to abrogate CD44-HA interaction (25). To determine whether 
CD44H41R-ARg  (CD44MuttLg)  might  recognize  other 
ligands in the ECM, normal rat and mouse tissues were tested 
for reactivity with CD44MutRg by indirect immunofluores- 
cence. CD44HRg bound to HA-containing areas in all organs, 
as previously demonstrated (8). However, CD44MutRg failed 
to bind the ECM of dermis, intestinal tissue (data not shown), 
skeletal musde, and renal papilla (Fig. 1), indicating that the 
soluble CD44MuttLg does not recognize ECM-bound HA 
and that  potential interactions  with other putative ligands 
are too weak to be revealed using this approach. These results 
provided a basis for comparing  the mutant  and wild-type 
CD44H in their capacity to enhance tumor growth in vivo 
and thereby assess whether CD44-HA interaction is the single 
most important factor in CD44-regulated tumor growth. A 
full-length  CD44H41R-A cDNA,  suitable for cell surface 
expression,  was synthesized and expressed in COS cells. Anti- 
CD44 mAbs were found to react with the COS cell-expressed 
mutant CD44 but binding of fluoresceinated hyaluronate was 
abrogated  (data not  shown). 
Expression of CD44 Polypeptides in a Human Melanoma Cell 
Line.  A  human  mdanoma call line,  MC  (11), was stably 
transfected with CD44H41R-A in a hygromycin-resistance 
gene-containing expression vector and hygromycin-resistant 
clones  sdected  and  tested  for  surface  CD44  expression. 
CD44H41R-A-expressing  cells did not display an increase 
in their capacity to attach to HA-coated surfaces with re- 
spect to parental MC cells (data not shown). The same mela- 
noma cell line had been used previously for stable expression 
of CD44H, CD44E, and CD44H cytoplasmic deletion mu- 
tants (CD44TL) in experiments designed to assess the role 
of CD44 in tumor cell adhesion to hyaluronate  as well as 
migration  on substrates in vitro (11). These studies had es- 
tablished that  CD44H  transfectants bind strongly to HA- 
coated surfaces whereas CD44E transfectants behave similarly 
to MC cells transfected with the selection plasmid only. MC 
cells  transfected with  a CD44H cytoplasmic domain dele- 
tion mutant attached to HA-coated surfaces weakly (11), but 
displayed no increase in migration  (11). An additional  cell 
line was developed, by transfecting the MC44E cell line with 
a  CD44H  cDNA  in  a  hygromycin-resistance  vector.  The 
resulting clones were selected for resistance to both hygromycin 
and neomycin.  CD44H/E  double transfectants  provided a 
means to assess whether coexpression of different isoforms 
with different HA binding potentials might have a distinct 
effect on tumor  development. 
All transfectants were compared for CD44 expression by 
indirect immunofluorescence using the F10-44-2 anti-CD44 
antibody that recognizes all isoforms (Fig.  2).  In addition, 
immunoprecipitation  of lysates from [3SS]methionine  radio- 
labeled transfectants  was performed, partly because the relative 
expression of CD44H and CD44E in double transfectants 
could not be distinguished on the basis ofimmunofluorescence 
alone (Fig.  3). For in vivo experiments,  transfectants  were 
selected for comparable levels of cell surface CD44 expres- 
sion.  MC44H41R-A  and  MC44H  ceils  displayed  similar 
reactivity with anti-CD44 mAb as assessed by indirect im- Figure  1.  Binding  of  CD44HRg  and 
CD44MutRg to ECM in vivo. Murine muscle  and 
renal tissue were snap-frozen and 5-#m sections 
were cut, mounted onto slides, and stained. Muscle 
(A-C) and renal papilla (D-F) reactivity  are shown 
with CD44 MutRg (A and/3), CD44HRg (B and 
E), and human IgG (C and F). 
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Figure  2.  Comparative  expression of  CD44 
in MC melanoma CD44 transfectants. FACS  | 
analysis of  MC melanoma transfectants show- 
ing reactivity with the Hermes-3 mAb. The 
cell lines were: (.4) MC-T; (B) MC44E; (C) 
MC44TL; (/3) MC44H/E; (E) MC44H41R-A; 
(F) MC44H; (G) MCc~2,6ST. 
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tion of CD44  from MC mela- 
noma CD44 transfectants. Lysates 
from  35S-radiolabeled transfec- 
tants  were immunoprecipitated 
with the F-10-44-2 antibody. Ly- 
sates were from: lane I, MC44TL; 
lane 2,  MC44H41R-A; lane 3, 
MC44H; lane 4, MC44E; lane 5, 
MC44H/E;  lane 6, MC~2,6ST. 
Molecular mass markers are shown 
on right. 
munofluorescence and immunoprecipitation (Figs. 2 and 3) 
whereas MC44E, and MC44H/E transfectants  expressed a 
higher level of CD44.  Control cell lines  included an MC 
derivative  expressing  the  neomycin resistance  gene  only 
(MC-T) and an MC line stably transfected with a B-galac- 
toside ot-2,6-sialyltransferase (MC-a2,6ST). The nomencla- 
ture used for the different transfectants and receptorglobulins 
is summarized in Table 1. 
Phenotypic Characterization of the Melanoma  Cell Transfec- 
tants.  All cell lines were tested for [3H]thymidine incorpo- 
ration to determine their baseline growth rate (Table 2). All 
of the transfectants,  with the exception of MC44E, had a 
comparable growth rate in vitro, which was lower than that 
of the MC-T control cell line (Table 2). 
Table  2.  Comparative  In  Vitro Proliferation of MC  Transfectants 
Cell line  [3H]Thymidine incorporation 
MC44E  70,190  (_+ 1,042) 
MC44H  20,134  (_+ 1,050) 
MC-TL  31,935  (+_ 665) 
MC-T  80,420 (+_ 1,042) 
MCc~2,6-ST  39,276  (_+ 2,242) 
MC41K-A  44,961  (-+ 1,600) 
MC44H/E  39,398  (_+1,304) 
Thymidine incorporation of MC melanoma transfectant cell lines. All 
experiments were done in triplicate. 
The phenotype of all transfectants was also characterized 
with respect to expression of adhesion molecules relevant for 
cell-cell and ceU-ECM interaction. Thus, the parental cell 
line and each transfectant were assessed  for/31 integrin V-LA1- 
VLA6 expression by indirect immunofluorescence  (Table 3). 
Comparisons between transfectants and the parental cells were 
made to ensure that expression of potentially relevant adhe- 
sion molecules had not been altered by the transfection itself 
and subsequent outgrowth under the selection  conditions. 
The MC melanoma cell line was found to express VLA3, 
5, and 6 but not VLA1, 2, and 4, and stable expression of 
CD44 appeared to have no significant  effect on the level or 
Table  1.  Characteristics  of CD44 Molecules Expressed in MC Cells and Corresponding Receptorglobulins 
eDNA transfected/MW  Promotion of transfectant 
of corresponding cell  adhesion  to HA coated  Keceptorglobulins 
Transfectants  surface  CD44  surfaces  derived (Rg) 
Binding to soluble 
and tissue  HA 
MC-T  none 
MC44H  CD44H/85  Kd 
MC-TL  CD44H cytoplasmic 
deletion/72  Kd 
MC44E  CD44E/130-150 Kd 
MC44H/E  CD44H  +  CD44E 
MC44H41K-A  CD44H mutant  (41 
Arg replaced  by Ala) 
/85  Kd 
MCc~2,6ST  Human ol-2,6- 
syalyltransferase 
-  (11) 
+  +  (9,  11,  23) 
+  (II) 
-  (9,  11,  23) 
nt 
-  (25) 
CD44HtLg  +  +  (8,  25) 
(8,  25) 
CD44EKg  + / - 
CD44Mut-Rg 
(25,  and present  study) 
-  (25,  and 
present  study) 
Characteristics of CD44 molecules expressed in MC transfectants and corresponding receptorglobulins. References are shown in brackets. For trans- 
fectant adhesion to HA-coated substrate,  + +  and  + : 6-10-fold and 2-5-fold increase of adhesion, respectively, compared with MC-T cells; -, 
background adhesion, typified by MC-T cells; nt,  not tested. 
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and VLA6 expression being observed in CD44H41K-A cells 
(Table 3). 
MC44H and MC44H41R-A  Cells Differ Primarily in Their 
Ability to Attach  to Synthetic Surface- and Tissue-bound Hyal- 
uronate.  To determine whether mutation of 41 Arg might 
alter CD44 interaction with molecules other than hyaluronate, 
that have been proposed to bind CD44 (3, 7, 18), MC44H, 
MC44H41K-A and MC-T cells were compared for attach- 
ment to plastic coated with hyaluronate, chondroitin sulfate, 
fibronectin, collagen type I, and collagen type VI. In these 
adhesion assays, the only significant functional difference be- 
tween MC44H and MC44H41K-A cells was their capacity 
to attach to hyaluronate-coated surfaces (Fig. 4). Importantly, 
attachment  of  the  two  transfectants  to  collagen  I  and 
fibronectin was comparable, and only slightly greater than 
that  of CD44-negative MC  controls.  In  these assays, no 
significant CD44-mediated binding to collagen VI and chon- 
droitin sulfate was observed.  Thus, mutation of 41 Arg ap- 
pears to selectively abrogate CD44-mediated MC melanoma 
cell attachment to hyaluronate in vitro. To determine whether 
the results of these assays reflect MC cell attachment in vivo, 
we performed adhesion experiments using rat and murine 
frozen  tissue  sections  overlayed  with  MC  transfectants. 
MC44H cells were observed to bind to dermis (Fig. 4), muscle 
and renal papilla  (data not shown), whereas no significant 
binding of MC44H41R-A or of MC-T cells was noted (Fig. 
4, and data not shown). Binding of MC44H cells could be 
abrogated by prior treatment of tissues with hyaluronidase 
(Fig. 4) but not with heparitinase or keratanase that served 
Figure 4.  In vitro adhesion assays. (,4) slCr- 
radiolabeled MC-T, MC44H, and MC44H41R-A 
cells were seeded onto 24-well plates (at 2  x  10  s 
cells/well)  previously  coated with HA, chondroitin 
sulfate, collagen I, collagen VI (each at 5 mg/ml) 
and fibronectin (1 mg/ml). Heat denatured BSA 
was used as a negative  control. Adhesion  assays  were 
performed at 4~  for 30 min with gentle shaking. 
Nonadherent cells  were washed away, adherent cells 
were lysed, and the released slCr was determined. 
Radioactivity is expressed in cpm. All experiments 
were done in triplicate and standard deviations are 
indicated.  (B) Adhesion of MC transfectants to 
frozen tissue sections. Untreated (panels  A, C, and 
D) and hyaluronidase-treated (panel B) tissue sec- 
tions of mouse skin were incubated with MC44H 
cells (panels A and B), MC44H41R-A cells (panel 
C),  and MC-T cells (panel D)  as described in 
Materials and Methods.  Adherent cells are indi- 
cated by arrow. The results shown are representa- 
tive of three  separate experiments. 
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Cell lines  Vlal  Vla2  Vla3  Vla4  Via5  Vla6 
MC-T  -  -  + +  -  +  + 
MC44H  -  -  + +  -  + +  + + 
MC44E  -  -  + +  -  + +  + + 
MC44TL  -  -  + +  +  + +  + + 
MC41R-A  +  -  + +  -  +  + 
MC44H/E  -  -  + +  -  + +  + + 
MCtx2,6-ST  -  -  + +  -  + +  + + 
B1 integrin expression of MC melanoma transfectant cells. Integrin expression  was evaluated  by indirect immunofluorescence  using specific anti-VLA 
mAb  + +, homogeneous staining of 70-100% of cells; +, variable staining of 10-70% of cells; +_, staining of isolated cells (<10%). 
as  controls  (data  not  shown).  Thus,  interaction  with 
hyaluronate in tissues appears to be the most potent mecha- 
nism of CD44H-mediated MC cell attachment to ECM, con- 
sistent  with  the in vitro binding  assays  above. 
CD44-HA  Interaction  Regulates  the  Rate of Local  Tumor 
Growth In  Vivo.  To determine the effect of CD44 expres- 
sion on the rate of melanoma growth in vivo, a pilot experi- 
ment was performed using three separate isolates of each trans- 
fectant (MC44H,  MC44E, MC44H41R-A,  MC44TL,  and 
MC-T).  An  equal number  of cells  from each transfectant 
(107) was injected subcutaneously into one SCID mouse and 
the animals monitored for visible tumor growth.  All three 
MC44H transfectants formed visible tumors within 18-21 d, 
whereas no tumors derived from MC44E,  MC44H41R-A, 
and  MC-T  cells  could  be  detected  30  d  after  injection. 
MC44TL  transfectants  formed measurable  tumors  within 
25-30 d of injection (data not shown). This pilot experiment 
showed  that  different isolates  of each  transfectant  formed 
tumors at comparable rates,  and allowed the selection of a 
single transfectant  of each type for subsequent  studies. 
To better evaluate the effect of expression of the different 
CD44  molecules on  tumor  development,  seven groups  of 
six SCID mice were injected subcutaneously with 6  x  106 
cells/animal,  each group  receiving a  different transfectant, 
The transfectants  included  MC-T,  MCa2,6ST,  MC44H, 
MC44E, MC44TL, MC44H41R-A, and MC44H/E. Animals 
were monitored  three times  a  week for first three weeks, 
and then daily for calibration  of tumor  growth  (Table 4). 
All animals were killed between days 36-50, when autopsy 
was performed, and the tumors excised and weighed. At day 
25 after injection, tumors were visible in animals receiving 
CD44H, CD44H/E, and CD44TL transfectants (Table 4 and 
Fig. 5). Between days 25 and 35,  a rapid increase of tumor 
volume  was  observed  in  animals  injected  with  CD44H, 
CD44H/E, and CD44TL transfectants but not with CD44E 
and CD44H41R-A transfectants (Fig. 5). At day 35, the av- 
erage weight of CD44H transfectant-derived tumors was 1,700 
mg compared with roughly 1000 mg for H/E transfectant-de- 
rived and 800 mg for CD44TL transfectant-derived masses. 
In contrast, only two animals receiving MC44H41IL-A ex- 
Table  4.  Tumor  Formation from MC Melanoma Transfectants 
Tumor weight* 
Cell line  Day 25  day 30  Day 35 
mg 
MC44E  7  (+  1)  7 (+  1)  7 (+  1) 
MC44H  17 (+  2.3)  174 (+  28)  1765 (+_  302) 
MC-TL  7 (_+  1)  66 (_+  19)  807 (_+  101) 
MC-T  7(+_  1)  7  (_+  1)  7(_+  1) 
MC-t~2,6-ST  7 (+_  1)  7 (_+  1)  7 (_+  1) 
MC41R-A  7 (_+  1)  7 (+_  1)  83 (_+  132) 
MC44H/E  15 (+_  14)  160 (_+  90)  1070 (_+  350) 
Tumor formation from MC mdanoma transfectants. The mean tumor size for each group (six animals/group), expressed in milligrams is indicated, 
along with standard deviations. 7 represents tumor size below measurable levels. 
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Figure 5.  CD44  MC melanoma transfectant-derived tumor develop- 
ment in vivo. The different MC transfectants are indicated. Tumor size 
is expressed  in milligrams. Each  bar represents the mean tumor size from 
six animals. 
pressing cells contained visible tumors at 35 d. To determine 
whether this tumor growth represents a significant enhance- 
ment  with  respect  to  the  controls,  animals  receiving 
MC44H41R-A, MC-T, and MCot2,6ST cells were observed 
for a total of 50 d. Between days 45 and 50, all animals  dis- 
played tumors averaging roughly 500 mg, which reflect the 
intrinsic tumorigenicity of the MC melanoma. No significant 
difference in tumor size was observed among the three groups 
of animals  (data not  shown),  indicating  that  expression of 
the CD44H mutant  does not confer a tumorigenic  advan- 
tage to melanoma cells. VLA expression was assessed by in- 
direct  immunofluorescence  in  tissue  sections of explanted 
tumors from two animals from each group. Tumors resulting 
from each of the various transfectants expressed the same 31 
integrins  as the transfectants  themselves (data not  shown), 
indicating  that in vivo growth had not altered the integrin 
ECM receptor repertoire  of the melanoma cells.  Similarly, 
CD44 expression was maintained  in all of the transfectant- 
derived tumors. 
CD44E Binds Hyaluronate Weakly and Is Shed  from the Sur- 
face of  MC Melanoma Transfectants.  In previous studies using 
human  lymphoma  transfectants  (9,  23)  and in  the present 
work, CD44E failed to promote cell attachment to hyaluronate 
in vitro or tumor development in vivo. In an attempt to de- 
termine whether this might be due to an intrinsic inability 
of CD44E to bind hyaluronate,  we developed a CD44ERg 
fusion protein  and examined its interaction  with ECM  on 
frozen tissue sections.  CD44ERg was found to bind renal 
papilla  interstitium  weakly compared  to  CD44HRg,  and 
binding could be abrogated by prior treatment of tissue with 
hyaluronidase (Fig.  6).  On the basis of this observation,  it 
might be expected that expression of CD44E should provide 
at least some tumor growth enhancement from corresponding 
transfectants.  Furthermore,  MC44H/E transfectants would 
be expected to form tumors at least at the same rate as CD44H 
expressors.  The failure of CD44E to promote MC cell tumor 
formation and the association of its expression with partial 
inhibition of CD44H-dependent tumor growth enhancement 
in the double transfectants  suggest that CD44E-mediated adhe- 
sion may be subject to inhibitory mechanisms at the cell sur- 
rice.  The failure to identify molecules that coprecipitate with 
CD44E and the observation that all known anti-CD44 mAb 
that recognize CD44H also recognize CD44E (25, and our 
unpublished  observations), render remote the likelihood of 
interactions between CD44E and cell surface molecules that 
might  mask or alter the conformation  of the HA-binding 
Figure  6.  Binding  of  CD44ERg to HA in vivo. 
Untreated and hyahronidase-treated  frozen tissue 
sections  of  rat kidney  were  incubated  with 10 #g/ml 
CD44HRg (A and B) or CD44ERg (C and D) 
followed  by a secondary  goat anti-human FITC- 
conjugated antibody. 
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CD44E from the cell surface.  To test this possibility, equal 
numbers  of MC44H,  MC44E,  and MC44H/E  cells  were 
[3SS]methionine  radiolabeled and CD44 immunoprecipitated 
from the supernatants  following a 72-h culture period. CD44E 
was found to be massively shed from MC  transfectants  as 
opposed to only slight shedding of CD44H (Fig.  7). Thus, 
the weak binding  of CD44E  to hyaluronan  coupled to its 
shedding from the cell surface may explain the inability of 
CD44E  to promote MC-derived tumor  development.  The 
massive shedding of the E isoform may partly inhibit CD44H- 
mediated attachment to ECM, providing a possible explana- 
tion for the intermediate growth rate of MC44H/E tumors. 
A  Strategy  for  Testing the Effect of Wild-type and Mutant 
Soluble Recombinant CD44 on Local Melanoma Growth.  The 
above results suggest that binding  of CD44 to hyaluronate 
plays a critical role in CD44-mediated enhancement  of local 
tumor growth. Because hyaluronate in solid tissues is bound 
to ECM proteoglycans, the validity of this observation can 
be tested by comparing the effect of soluble CD44HRg and 
CD44MutlLg on local tumor formation of exogenously ad- 
ministered  CD44H-expressing  melanoma  cells.  Based  on 
the tissue-binding capacity of CD44HKg, and the observa- 
tion  that  CD44HRg  can  block  hematogenous  spread  of 
CD44H-expressing lymphomas (28), it would seem reason- 
able to expect that CD44HRg might compete with cell sur- 
face CD44H  for hyaluronate binding,  thereby possibly in- 
hibiting  tumor growth.  CD44MutRg,  on the other hand, 
should  have  no  effect.  Previous  work  had  indicated  that 
CD44Rg might have a short half-life in vivo (28), suggesting 
that  any functional  study is likely to require  repeated and 
frequent administration of the fusion protein. Because repeated 
daily local injections of soluble CD44 would represent a tech- 
nical difficulty in determining the exact tumor cell injection 
site, in addition to causing animal discomfort, 100 #1 osmotic 
pumps containing CD44HRg, CD44MutKg, or human IgG 
were implanted subcutaneously at the site of subsequent tumor 
cell injection. These pumps administer their contents by con- 
tinuous infusion over a period of 7 d, and the injected medium 
Figure  7.  Shedding  of CD44 
from the surface of MC transfec- 
tants. Equal numbers of MC44H, 
MC-T, MC44E, and MC44H/E 
cells were 35S-radiolabehd and 
culture  supernatants harvested 
72 h  after labeling. CD44 was 
immunoprecipitated from the su- 
pernatants using anti-CD44 mAb 
and protein A-Sepharose beads. 
Supernatants were from: lane 1, 
MC-T cells; lane 2, MC44H  cells; 
lane 3,  MC44E cells; lane 4 
MC44H/E cells; lane 5: immu- 
noprecipitation  of  cell surface 
CD44H and E from MC44H/E 
transfectants.  Molecular  mass 
markers (kD) are indicated. 
Figure 8.  CD44 expression by 
B16F10  melanoma  cells. Immunopre- 
cipitation of CD44 from 35S-radio- 
labeled cell lysates was  performed 
using the IM7 mAb. Lysates were 
from: lane I, MC-T; hne 2, B16F10; 
lane 3, MC-CD44H. Molecular  mass 
markers are shown on right. 
diffuses into the subcutaneous tissues in the vicinity of the 
pump. To be optimally exploited, this strategy would require 
the use of CD44H-expressing, hyaluronate-binding cells which 
rapidly form tumors in vivo, so that the effect of the recep- 
torglobulins might readily be determined.  To this end,  the 
routine  melanoma  B16F10 was selected. 
Characterization of  Murine Melanoma CD44 Expression and 
Function.  The use of the murine B16F10 melanoma offers 
several advantages.  First,  B16F10 cells display an aggressive 
growth pattern in nude mice, allowing rapid assessment of 
the effect of CD44 receptorglobulins.  Second, B16-derived 
tumors are pigmented and their local spread can be readily 
visualized without resorting  to surgical procedures.  Third, 
if CD44HRg were to prove effective in blocking tumor for- 
mation in this model,  it would provide additional  support 
for the importance  of CD44-HA interaction,  and suggest 
50000 
40000 
30000 
E  Q. 
o 
20000 
10000 
#  / 
HA  CS  Medium 
Binding orB16  melanoma  cells  to HA. Binding to HA-, chon-  Figure  9. 
&oitin sulfate-, and PBS-coated wells is expressed as stCr radiolabd 
released from adherent cells  after lysis  by detergent. All experiments were 
done in quadruplicate. 
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 that any potential species-specific  CD44-1igand interactions 
might only play a minor role in promoting tumor develop- 
ment. B16F10 cells tested positive for reactivity with the anti- 
CD44 mAb IM7, and immunoprecipitation of B16F10 ly- 
sates with IM7 revealed an 85-kD isoform, corresponding 
to CD44H, and an additional  100-kD species (Fig. 8). The 
cells were observed to adhere to HA-coated surfaces (Fig. 9). 
Local Infusion of  CD44HRg Blocks Tumor Growth.  An irfifial 
pilot study was performed to determine whether infusion 
of CD44HRg had any blocking effect at all on local tumor 
growth. Four animals were injected with 5  x  106 B16 mela- 
noma cells each, in the immediate vicinity of the implanted 
pump. Two of  the animals had pumps containing human IgG 
at 1.5 mg/ml, while two other mice had similar pumps con- 
taining CD44HRg at 1.5 mg/ml. At the end of 7 d both 
sets of animals showed tumor growth, but the tumors in 
animals bearing CD44HRg-infusing  pumps were significantly 
smaller than their counterparts in animals infused with IgG 
(data not shown). Because the B16 melanoma grows rapidly 
in vivo, it seemed likely that the amount of CD44HRg in- 
fused might be insufficient to block tumor development from 
such a large number of injected cells. To optimize the condi- 
tions,  the experiments were repeated by injecting each an- 
imal with 125  x  103 cells. Three groups of ten animals were 
used, carrying pumps containing 0.1 ml of either human IgG, 
CD44HRg,  or CD44MutRg,  each at 6 mg/ml. 8 d after 
tumor injection, and 1 d after the cessation of immunoglob- 
ulin and receptorglobulin delivery  by the osmotic pumps, eight 
animals from each group were killed and tumor growth as- 
sessed. Whereas both groups of animals receiving human IgG 
and CD44MutRg revealed large tumor masses (1-2 cm in 
diameter), no tumor formation was observed in mice infused 
with CD44HRg (Fig. 10). Two animals from each group 
were followed for an additional week in the absence of im- 
munoglobulin or receptorglobulin administration. Although 
tumor masses appeared in the animals which had previously 
received CD44HKg, they measured 2-3 mm compared with 
3-4 cm for tumors derived from animals that had been in- 
fused with IgG and CD44MutRg (data not shown). Addi- 
tional control experiments were performed by injecting animals 
with the same number of B16 melanoma cells in 0.1 ml of 
a 6-mg/ml solution of CD44Rg or human IgG, but without 
continuous CD44Rg infusion.  Although the presence of 
CD44Rg at the time of injection significantly slowed down 
the tumor growth with respect to IgG, tumors were visible 
3 d after injection and had grown to a diameter of 0.5-0.8 
cm by day 8  (data  not  shown).  Continuous infusion of 
CD44Kg therefore appears necessary to effectively  block local 
melanoma growth. Tumor growth inhibition by CD44Kg 
was not due to a direct effect on the melanoma cells since 
B16 melanomas cultured in the presence of 6 mg/ml CD44Kg 
did not show a significant modification in their growth rate 
(Table 5). 
Discussion 
HA has been observed at sites of tumor invasion (29) and 
several studies have suggested that HA might in some way 
Table  5.  Proliferation Assay of Murine Melanoma B16 Cells 
CD44HKg  Human IgG  Standard medium 
18,479  +  928  20,253  +_  1,377  20,435  +  1,861 
Thymidine incorporation of BI6FI0 cells growth in the presence of 
CD44HKg and human IgG, All experiments were done in triplicate. 
be associated with tumor aggressiveness (30, 31). This no- 
tion is supported by observations that high expression of the 
HA receptor, CD44, correlates with aggressiveness of lym- 
phoid tumors (32) and invasiveness  of bladder carcinomas (31). 
Our own studies have demonstrated that expression of an 
HA binding form of CD44 (CD44H) in a human lymphoma 
significantly augments the rate of local tumor development 
in vivo as well as the rate of tumor formation in various organs 
as a result of hematogenous dissemination  (23). Tumor de- 
velopment resulting from hematogenous dissemination  of 
CD44H-expressing  lymphoma cells could be blocked  by 
soluble CD44Kg  (28). The choice of melanomas for the 
present experiments was twofold. First, most melanomas ex- 
press high levels of CD44H (13, 33, 34), which might regu- 
late their dermal penetration and intradermal growth, espe- 
cially since dermis is abundant in HA (35). Assessment of 
the role of CD44 expression in melanoma growth may there- 
fore have direct biologic and clinical  relevance.  Second, previous 
experiments on the role of CD44 in tumor growth promo- 
tion were performed using lymphoma cells, and it seems  critical 
to determine whether CD44 isoforms behave in a similar way 
in cells of different origin or whether their impact on tumor 
growth varies according to the cell type in which they are 
expressed. Melanomas, being of neuroectodermal origin, pro- 
vide a suitable counterpart to mesoderm-derived lymphoid 
cells. The present study provides clear evidence that the two 
CD44 isoforms tested, CD44H and CD44E behave  in a similar 
manner in melanomas and in lymphomas with regard to the 
regulation of tumor growth in vivo. 
Interestingly, expression of CD44H cytoplasmic tail dele- 
tion mutants significantly promotes tumor growth although 
not to the same degree as wild-type CD44H. This is consis- 
tent with the observations that cells expressing CD44H cy- 
toplasmic deletion mutants can still adhere to hyaluronate- 
coated surfaces but with significantly lower efficiency than 
wild-type CD44H-expressing  transfectants (11, 36). The cy- 
toplasmic domain of CD44 is thought to interact with the 
cytoskeleton (37-39) and its presence  is required for cell migra- 
tion on HA-coated substrates (11). Expression of the cyto- 
plasmic tail may also stabilize the cell surface conformation 
of CD44 and/or facilitate its aggregation on the cell surface 
which is proposed to be required for optimal HA binding 
(40, 41). However, the present observations clearly suggest 
that biologically significant interaction between cell surface 
CD44H and ECM-bound HA can occur in the absence of 
the cytoplasmic tail. 
Similar  to  lymphoma transfectants,  CD44E-expressing 
63  Bartolazzi  et al. melanoma cells were not observed to display enhanced tumor 
formation with respect to controls. We have shown here that 
a CD44EKg fusion protein binds HA in tissues, although 
not as strongly as CD44HRg,  supporting the notion that 
the presence of variably  spliced exons may influence HA 
binding ability of CD44. Furthermore, CD44E was observed 
to be spontaneously  shed from the surface of MC transfec- 
tants,  providing a potential explanation  for its inability  to 
promote MC-derived tumor development,  and partial inhi- 
bition  of CD44H-dependent MC44H/E  tumor  growth. 
These observations raise two interesting possibilities. The first 
is that selective shedding of CD44 isoforms may play a role 
in the regulation of CD44-associated cell-substrate  interac- 
tions.  The  second  is  that  shedding  may provide  a  cell 
type--specific selection pressure for CD44 splice variant ex- 
pression, since CD44 is not observed to be shed from several 
human tumor cell lines that constitutively express CD44E 
(Bartolazzi,  A., and I.  Stamenkovic, unpublished  observa- 
tions).  Elucidation of mechanisms that determine preferen- 
tial shedding of one CD44 isoform with respect to another 
will require further study. 
The  principal  finding  in  the  present  work  is  that 
CD44H-HA interaction provides an important mechanism 
by which CD44H-mediated promotion of tumor growth is 
regulated in vivo. This observation  is based on the use of 
a recombinant CD44H molecule containing a point muta- 
tion that changes an arginine residue at position 41 of the 
extracellular domain to alanine (25). The cell surface-expressed 
CD44H mutant does not bind soluble (Peach, R., and A. 
Aruffo, unpublished observations) or surface-bound HA and 
melanoma cell transfectants expressing the CD44H mutant 
fail to show the rapid tumor formation in SCID mice charac- 
terized by wild-type CD44H-expressing  counterparts. In our 
assays, transfectants expressing the mutant CD44 molecule 
and MC44H cells bound comparably to a variety of substrates 
that have been advocated as CD44-binding molecules. Thus, 
it would appear that the point mutation of 41 Arg in the 
melanoma model presented here does not alter other known 
CD44 adhesive properties. It would also appear unlikely that 
the point mutation results in a CD44 signaling defect, since 
MC44TL cells, which express a cytoplasmic deletion mutant 
that cannot promote cell migration on hyaluronan, and there- 
fore appropriate  intracellular  signaling,  form tumors more 
rapidly than parental and CD44H41R-A cells. Although we 
cannot exclude the possible participation  of another,  as yet 
unidentified,  CD44 ligand, these observations strongly sup- 
port the notion that communication between the extracel- 
lular domain of CD44H and its principal ligand, HA, is crit- 
ical for CD44-dependent augmentation of tumor growth. 
CD44H expression  may therefore provide a general pathway 
for the regulation of tumor development  regardless of the 
histologic nature of the tumor. However, it has recently  been 
demonstrated that CD44H on normal murine leukocytes does 
not bind HA with high affinity, and that leukocyte activa- 
tion is required for high affinity binding to occur (42). This 
observation suggests that leukocyte activation may result in 
a conformational change of CD44H that augments its HA 
binding affinity. In several  human tumors that we have tested, 
CD44H appears to be constitutively expressed in an HA- 
binding conformation (9,  11,  34,  Bartolazzi,  A.,  and  I. 
Stamenkovic, unpublished observations), but there are reports 
that some tumors expressing this isoform do not bind HA 
(33). Assessment of the HA-binding capability that CD44H 
confers to tumor cells may therefore be a superior indicator 
of potential  tumor aggressiveness than CD44H expression 
alone. 
We had previously  shown,  using  a lymphoma model, 
that soluble CD44Rg could effectively  inhibit hematogenous 
dissemination of CD44H-expressing, HA-binding lymphoid 
tumor cells (28). In the present study, CD44HRg is observed 
to block local tumor development from highly tumorigenic 
melanoma  cells, and  underscores  the  critical  nature  of 
CD44H-HA interaction,  since CD44MutRg has no inhibi- 
tory effect on B16 melanoma growth. Optimal blocking of 
tumor growth appears to require  continuous infusion  of 
soluble CD44HRg.  This may be due in part to the short 
half-life of the molecule in vivo (28), but may probably also 
be attributed to the high turnover rate of HA (35). In addi- 
tion to confirming the importance of CD44H-HA interac- 
tion in regulating the rate of tumor formation, these obser- 
vations  suggest  that  local  infusion  of CD44HRg  might 
provide a potential approach to helping contain regional tumor 
spread. 
Recent work has suggested that a distinct CD44 isoform 
might play an important role in determining the metastatic 
proclivity of an adenocarcinoma in rats (16). However, an- 
other study has shown that expression of the corresponding 
human homolog is downregulated in human squamous car- 
cinoma metastases (43). Whether the metastasis-promoting 
effect of this isoform in rat adenocarcinoma cells is due to 
its interaction with HA or other putative ligands in host 
tissues remains to be determined. It is possible, for example, 
that  certain  tumor  cells might  induce post-translational 
modifications of variable exon-encoded sequences that facili- 
tate interactions with ligands other than HA and that may 
influence metastatic tumor cell behavior. This view is sup- 
ported by studies showing that addition of chondroitin sul- 
fate side chains to CD44 can promote its interaction  with 
fibronectin  (18). 
In addition to HA and fibronectin, CD44H has been ob- 
served to display  affinity for chondroitin sulfate  (8, 9). Whereas 
recognition of some of the alternative ligands by CD44H 
may have potential physiologic relevance in certain cellular 
interactions  (3), the present study suggests that interaction 
with ECM-bound HA constitutes a critical step in CD44H- 
mediated promotion of tumor growth. The precise mecha- 
nism by which enhancement of tumor formation might occur 
is unclear. One possibility is that HA may trigger CD44- 
mediated signals, a view that is supported by studies showing 
that antibody stimulation of CD44 augments cytokine produc- 
tion by monocytes (44), and that macrophage interaction with 
HA may result in growth factor secretion (45). An alterna- 
tive view might be that CD44H participates in HA degrada- 
tion (46), which might facilitate tumor cell invasion of host 
64  Interaction between CD44 and Hyaluronate in Tumor Development Regulation tissues. The observation that tumor cells expressing CD44 
cytoplasmic deletion mutants form tumors more rapidly than 
CD44-negative  controls would  seem to  support  the latter 
possibility.  In  the  simplest  scenario,  consistent  with  our 
previous and present results, HA might serve as a molecular 
bridge,  promoting  tumor cell interaction with host  tissue 
stroma, which is critical to both primary and metastatic tumor 
growth. 
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